Persistent High-Risk Human Papillomavirus Infection
DAREDaré Bioscience, Inc.Catalyst overview
Research summary
This catalyst tracks a Phase 2 data readout for DARE-HPV (Protease Inhibitor) in Persistent High-Risk Human Papillomavirus Infection. The expected timing is based on the latest available company guidance and may change.
05/14/26:- DARE-HPV is advancing into a Phase 2 study in May 2026. 05/18/26:- Phase 2 trial initiated; topline data expected in 2027. 08/13/26:- Phase 2 study enrolled toward approximately 100 women. Topline results are expected in 2027.
Verification
Confirm timing and program details against the company announcement or filing.